Evidence map›Paper›PMID 21569410›Full record

ArticleBMC complementary and alternative medicine2011

A hepatoprotective Lindera obtusiloba extract suppresses growth and attenuates insulin like growth factor-1 receptor signaling and NF-kappaB activity in human liver cancer cell lines.

Christian Freise, Martin Ruehl, Ulrike Erben, Ulf Neumann, Daniel Seehofer, Ki Young Kim, Wolfram Trowitzsch-Kienast, Thorsten Stroh, Martin Zeitz, Rajan Somasundaram

Open access · goldAbstract read
In one paragraph

Article in BMC complementary and alternative medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 31 citations in OpenAlex.

  1. Selective Inhibition ofPharmaceutics · 2025
    Article
  2. Nutrients · 2024
    Article
  3. Mitigating Effect ofMolecules (Basel, Switzerland) · 2021
    Article
  4. Therapeutic Potential ofPlants (Basel, Switzerland) · 2020
    Review
  5. Antiviral Effects ofAntibiotics (Basel, Switzerland) · 2020
    Article
  6. Antioxidants (Basel, Switzerland) · 2020
    Article
  7. Review
  8. IGF-I receptor as an emerging potential molecular-targeted for hepatocellular carcinoma in vitro and in vivo.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  9. Article
  10. Article
  11. Article
  12. Abnormal expression of insulin-like growth factor-I receptor in hepatoma tissue and its inhibition to promote apoptosis of tumor cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013
    Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Christian FreiseDepartment of Gastroenterology, Infectiology and Rheumatology, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany.
Martin Ruehl
Ulrike Erben
Ulf Neumann
Daniel Seehofer
Ki Young Kim
Wolfram Trowitzsch-Kienast
Thorsten Stroh
Martin Zeitz
Rajan Somasundaram
Charité - Universitätsmedizin Berlin · DEBerliner Hochschule für Technik · DEUniversitätsklinikum Aachen · DEWonkwang University · KR

Funding

Medical Research Council
6 · The paper itself

Abstract

backgroundIn traditional Chinese and Korean medicine, an aqueous extract derived from wood and bark of the Japanese spice bush Lindera obtusiloba (L.obtusiloba) is applied to treat inflammations and chronic liver diseases including hepatocellular carcinoma. We previously demonstrated anti-fibrotic effects of L.obtusiloba extract in hepatic stellate cells. Thus, we here consequently examine anti-neoplastic effects of L.obtusiloba extract on human hepatocellular carcinoma (HCC) cell lines and the signaling pathways involved.

methodsFour human HCC cell lines representing diverse stages of differentiation were treated with L.obtusiloba extract, standardized according to its known suppressive effects on proliferation and TGF-β-expression. Beside measurement of proliferation, invasion and apoptosis, effects on signal transduction and NF-κB-activity were determined.

resultsL.obtusiloba extract inhibited proliferation and induced apoptosis in all HCC cell lines and provoked a reduced basal and IGF-1-induced activation of the IGF-1R signaling cascade and a reduced transcriptional NF-κB-activity, particularly in the poorly differentiated SK-Hep1 cells. Pointing to anti-angiogenic effects, L.obtusiloba extract attenuated the basal and IGF-1-induced expression of hypoxia inducible factor-1α, vascular endothelial growth factor, peroxisome proliferator-activated receptor-γ, cyclooxygenase-2 and inducible nitric oxide synthase.

conclusionsThe traditional application of the extract is confirmed by our experimental data. Due to its potential to inhibit critical receptor tyrosine kinases involved in HCC progression via the IGF-1 signaling pathway and NF-κB, the standardized L.obtusiloba extract should be further analysed for its active compounds and explored as (complementary) treatment option for HCC.

Indexed as

LinderaAngiogenesis InhibitorsAntineoplastic Agents, PhytogenicApoptosisCarcinoma, HepatocellularCell LineCell Line, TumorCell ProliferationCyclooxygenase 2Cyclooxygenase 2 InhibitorsHumansHypoxia-Inducible Factor 1, alpha SubunitInsulin-Like Growth Factor ILiver NeoplasmsNF-kappa BNitric Oxide Synthase Type IIAngiogenesis InhibitorsAntineoplastic Agents, PhytogenicCyclooxygenase 2Cyclooxygenase 2 InhibitorsHypoxia-Inducible Factor 1, alpha SubunitInsulin-Like Growth Factor INF-kappa BNitric Oxide Synthase Type IIPlant ExtractsReceptor, IGF Type 1Vascular Endothelial Growth Factor A

Identifiers

PMID21569410
PMCPMC3117754
OpenAlexW2085573903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.